The biological mechanism involved in anticancer properties of amniotic membrane

Ameneh Jafari,1,2 Hassan Niknejad,3 Mostafa Rezaei-Tavirani,2 Caitlin D’Amico,4 Hakimeh Zali2

1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4University of Vermont Medical Center, Burlington, VT, USA; 5Nanotechnology and Tissue Engineering Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

The main role of amniotic membrane (AM), or amnion, is to protect the fetus from drying out and create an appropriate environment for its growth. AM is also a suitable candidate for the treatment of various diseases due to its unique characteristics. In recent years, a new line of research has focused on the anticancer properties of amnion and its potential use in cancer treatment. The in vitro and in vivo studies indicate the anti-proliferative and pro-apoptotic activities, as well as the angioregulatory and immunomodulatory properties of the amniotic membrane. However, the exact mechanism and molecular basis of these anticancer effects of AM are not fully elucidated. This paper presents an overview of the latest findings and knowledge about the anticancer effects of AM and its underlying molecular mechanisms, which is crucial for the application of amnion in cancer therapy.

Introduction

Amniotic membrane (AM), or amnion, is an extraembryonic envelope that surrounds the fetus. Amnion is a transparent membrane without nerves, muscles, and lymphatic vessels. It consists of three histological layers, including epithelial, basal, and stromal layers. The stromal layer is divided into compact, fibroblast, and spongy layers (Figure 1).1 Two types of cells have been isolated from amnion, namely amniotic epithelial cells (AEC) and amniotic mesenchymal stromal cells (AMSC).1 Both populations express the specific surface and intracellular markers of stem cells, such as stage-specific embryonic antigen-4 (SSEA-4), tumor-related antigen-1-60 [TRA-1-60] and TRA-1-81, and can differentiate into various cell types.2 Amniotic cells show low to intermediate expression of human leukocyte antigen (HLA)-A, -B, -C, -D, and HLA-QR antigens, without expression of HLA-G.1 Furthermore, these cells do not stimulate immune responses and allograft rejection after transplantation due to lack of immunogenicity.1,3

The AM has many properties that make it suitable for clinical use, as it: i) provides an extracellular matrix that allows the attachment and proliferation of cells; ii) stimulates epithelialization and inhibits scarring;4,5 iii) acts as an angiomodulator; iv) synthesizes the natural inhibitors of metalloproteinases;6,7 v) possesses anti-inflammatory, hemocompatibility, and anticancer properties; vi) is a non-tumorigenic tissue; and vii) has useful mechanical properties.8 Another advantage of AM is that its use is ethically acceptable because the placenta and AM are usually discarded after childbirth.9,8

The first documented use of AM for clinical application dates back to 1910 when Davis used AM for the reconstruction of skin.1,5,8 AM is now most commonly used in ophthalmology, especially in the reconstruction of the cornea and the ocular conjunctiva, as it promotes the regeneration of the epi-body and inhibits inflammation and scarring.5 In addition, AM is also used in dermatology for the treatment of burns and chronic ulcers as well as some surgical procedures, such as the prevention of post-surgery adhesions, abdominal surgery, prevention of peritoneal adhesions, gastrointestinal treatment, and reconstruction of the urinary tract.10 Amniotic membrane works as a scaffold for proliferation and differentiation due to the presence of collagen types I, III, IV, V, and VI, fibronectin, nidogen, elastin, and hyaluronic acid.1,3,4 Furthermore, there are studies that indicate the anticancer effects of AM, but the mechanism of this effects is yet abstruse and unclear.11,12

In this review, we will discuss the anticancer properties of various derivatives of amniotic membrane, as cells or conditioned medium. Moreover, we will highlight the biological pathways that AM uses to carry out anti-carcinogenic activity.
**Hallmarks of cancer**

Cancer is the second most common cause of death in humankind. Despite advances in the prevention and treatment of cancer, the number of cancer-related illnesses and various risk factors (smoking, obesity, nutrition, and environmental factors) continue to increase. Tumors are complementary systems that include cancer cells, immune system cells, endothelial cells, and cancer-associated fibroblasts. Hanahan and Weinberg described the essential properties of cancer cells in 2000 and 2011, including: i) the ability of continuous cell division; ii) non-responsiveness to signals that inhibit cell division; iii) avoidance of apoptosis; iv) non-terminal potential for mitosis; v) stimulation of angiogenesis; vi) invasiveness and metastasis; vii) genomic instability; viii) reprogramming of cellular energy metabolism; ix) stimulation of inflammation; and x) avoidance of the immune system.

Several studies have aimed to clarify the application of stem cells in cancer therapy. Therefore, identification of alternative sources of stem cells with optimal biological proprieties and easy yield or isolation has become a crucial issue in current studies. The AM is a promising alternative source for this purpose.

Previous authors have reported the safe and successful application of cryopreserved amniotic membrane and freshly frozen AM graft for non-melanotic tumors as well as melanoma. The use of AM graft has improved the local surgical outcomes by refining healing and reducing scarring and has made possible the excision of wider margins around the tumor.

Tabatabaei et al. investigated the potential of human amniotic epithelial cells (hAEC) as a vaccine for cancer prevention and therapy in a mouse model of colon adenocarcinoma. They observed considerable reduction in tumor burden in the tumor-bearing mice immunized with hAEC.

**Table 1. The anticancer effect of amniotic membrane cells or conditioned medium and underlying mechanism.**

| Cell type                                      | Targeted cell line / Cancer type | Cellular effect                                      | Molecular effect                                      | Ref |
|------------------------------------------------|----------------------------------|------------------------------------------------------|-------------------------------------------------------|-----|
| Amniotic epithelial cells                      | Human cervical carcinoma (Hela)  | Decrease of cancer cell viability                     | Increase in caspase-3,-8                               | 11  |
| and breast cancer (MDA-MB-231)                |                                  | Anti-angiogenic                                       |                                                      |     |
|                                                |                                  | Apoptosis induction                                   |                                                      |     |
| Amniotic mesenchymal cells                     | Acute myelogenous leukemia (KG1) | Anti-proliferative                                     | Cell cycle arrest in G0/G1 phase                      | 31  |
| (Jurkat), T-cell leukemia (Jurkat), monocytes  |                                  |                                                      |                                                      |     |
| from histiocytic lymphoma (U937),              |                                  |                                                      |                                                      |     |
| Human cervical carcinoma (Hela)                |                                  |                                                      |                                                      |     |
| Amniotic mesenchymal cells                     | Brain tumor (Ch-glioma)          | Inhibition of cell migration                           | ---                                                  | 36  |
|                                                |                                  | Apoptosis induction                                   |                                                      |     |
| Amniotic mesenchymal and/or                   | Hepatocarcinoma                  | Apoptosis Induction                                   | - Reduction the metabolic activity                     | 39  |
| mesenchymal cells                              | (HuH7, HepG2, and Hep3B2.1-7)    |                                                      | - Increase in cytochrome. C release,                  |     |
|                                                |                                  |                                                      | BAX/BCL2 ratio,                                       |     |
|                                                |                                  |                                                      | - Increase in caspase 3, caspase 8, and caspase 9     |     |
|                                                | T-cell leukemia (Jurkat)          | Apoptosis induction                                   | Caspase-3 pathway                                     | 43  |
| hAM-protein extract                            | Prostate cancer (PC3),           | ---                                                  |                                                      |     |
| colon cancer (WiDr, C2BBe1, LS1034),           |                                  |                                                      |                                                      | 47  |
| pancreas cancer (PANC-1),                     |                                  |                                                      |                                                      |     |
| hepatocarcinoma (HepG-2, Hep3B2.1-7),         |                                  |                                                      |                                                      |     |
| breast cancer (MCF7, HCC1954),                |                                  |                                                      |                                                      |     |
| bile ducts (TPF-1)                             |                                  |                                                      |                                                      |     |
| hAM-protein extract                            | Prostate cancer (PC3)            | Reduction of cell proliferation                       | Decrease in gene expression and HSP90 protein expression | 75  |
Amniotic membrane inhibits cancer cells proliferation

Normal cells accurately control the biosynthetic pathways and release of signaling molecules that stimulate their growth and cause mitotic depletion or inhibit cell growth and prevent their entry into the mitotic division. This maintains the normal architecture and function of the tissue. During development, cancer cells gain the ability to ignore cellular signals that prevent cell division, which leads to the continuation of their mitotic divisions. Cell cycle proteins, in particular cyclins and cyclin-dependent kinases, as well as cell cycle checkpoint proteins constitute potential therapeutic targets in cancer therapy. Seo et al. reported the anticancer properties of amnion for the first time in 2008. They proposed amnion for cancer treatment owing to its anti-angiogenic, immunoregulatory, and pro-apoptotic properties. Afterwards, researchers like Kim, Niknejad, Mamede, and colleagues tested this hypothesis. Some of studies on anti-cancer effects of amniotic membrane cells or its derived conditioned medium and underlying mechanisms have been summarized in Table 1. The anticancer effects of AM and its cells are due to the release of fatal factors and cytokines for tumor cells, such as macrophage granulocyte colony stimulating factor, neurotrophin-3, transforming growth factor beta (TGF-β), tumor necrosis factor alpha (TNF-α), tumor necrosis factor beta (TNF-β), C-C motif chemokine ligand 18 (CCL18), protected dopamine neurotrophic factor, macrophage stimulating factor, granulocytic chemotactic protein (GCP-2), brain-derived neurotrophic factor (BDNF), and interleukin-2 (IL-2), IL-4, IL-6, and IL-8. The anti-tumor effects of these factors have been described and they could participate in the mechanisms involved in the inhibition of cancer cell proliferation.

The inhibitory effect of AM on the proliferation of cancerous cells has been demonstrated via different ways, including attenuation of gene expression of certain cyclins (cyclin D2/E1/H) and cyclin-dependent kinase-2 (CDK2), CDK4, CDK6, which promote the progression of the cell cycle, reduction of cell cycle stimulators, and increase of cell cycle suppressors such as p53 and...
Amniotic membrane promotes cancer cells apoptosis

Apoptosis is a programmed cell death that is a natural barrier to cancer development.32 Due to some genetic and chromosomal mutations, natural cells turn into cancerous ones.34 Many studies have revealed that AM (as its cells or conditioned medium) can stop the proliferation of cancer cells or even trigger their apoptosis.35-42 The reduced survival of cancer cells under the influence of AM is due to cytotoxic factors excreted by AEC as well as AMSC (Figure 2).11,12,31,35,43,44 Niknejad et al. reported a significant increase in caspase-3 and caspase-8 expression in HeLa and MDA-MB-231 cells after treatment with hAEC-CM.11 Bcl-2/caspase pathway propounded as another mechanism of AM to induce apoptosis in tumor cells. In one study, Jiao et al. showed the inhibition of cell migration and induction of apoptosis by AMSC, leading to a reduced proportion of brain tumors of the gliomas in rats.36 The authors concluded the decreased ratio of Bcl-2/Bax due to increased expression of apoptotic markers (e.g., Bax, caspase 8, and caspase-3) and decreased expression of anti-apoptotic marker (Bcl-2) after treatment of glioma cells with AM, is responsible for triggering apoptosis in these cells.36

Amniotic membrane cells and their conditioned medium induce apoptosis in several cell lines (HeLa cervical cancer cells, hepatocarcinoma cancer cells HepG2, MDA-MB-231 breast cancer cells, Hep3B2.1-7, Hep3B2.1-8, and HuH7, as well as in animal models (glioma in BALB/C mice, breast tumor in BALB/C nu mice, and hepatocarcinoma in BALB/C nu/nu mice).38-40

We have previously reported that the conditioned medium from AM inhibits the expression of the HSP90 heat shock protein, which triggers cell cycle inhibition, apoptosis, and the inhibition of angiogenesis.41 HSP90 prevents apoptosis by activating NF-κB on the one hand and binding to APAF-1 (apoptotic protease activating factor-1) and blocking the caspase9 cascade on the other hand.42 Additionally, another study has shown that the protein extraction of AM, prepared by homogenization and sonication of AM, trig- ers the apoptosis of carcinoma cells in vitro.39 The obtained results in that study indicate hAM protein extract is able to induce cell death pathway depend on the biological and genetic profile of the cancerous cell line. The authors reported stimulation of the intrinsic apoptotic pathway (as an increase in cytochrome C release, Bax/Bcl2 ratio, caspase 3, and caspase 9) in HuH7 cell line, while induction the extrinsic apoptotic pathway (as an increase in caspase 3 and caspase 8) by hAM protein extract in HepG2 and Hep3B2.1-7.39

Li et al. demonstrated the effect of AECs supernatant on apoptosis of Jurkat cells.43 They suggested that AECs induced apoptosis through caspase pathways. Their results indicated that AECs express human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), TNF-α, and Fas ligand (FasL).43 The role of these factors in participating in apoptosis is well known.44 The authors demonstrated that FasL plays a major role in AEC-mediated apoptosis.43

Amniotic membrane reduces cancer cells metabolism

For uncontrolled cell proliferation, a change in cellular energy metabolism is essential, which allows the growth and survival of cancer cells. In comparison with normal (healthy) cells, which receive energy primarily by oxidative phosphorylation, cancerous cells mostly generate energy through aerobic glycolysis (i.e., Warburg effect).45 Such changes in cancer cell vectors allow for increased energy production, sufficient biosynthesis of macromolecules, maintenance of the redox balance, and thus the emergence of tumors.16,46 Proteins extracted from AM, prepared by homogenization and sonication, affect the metabolism of cancer cells (Figure 2). Mamede et al. demonstrated that the protein extracted from AM inhibits the energy metabolic activity in 14 different cell lines and even more than 50% of the metabolic activity in five cell lines (PC3, WiDr, PANC-1, HepG2, and Hep3B2.1-7), as well as in esophageus cancer cells, osteosarcoma, and melanoma.47 Consequently, they predict that the response of cancer cells to AM is specific to the genetic profile or the type of cancerous cell.47

Amniotic membrane has immunosuppressive effect on cancerous cells

Multiple studies have shown that the immune system can transform normal cells into cancer cells.44,46 Inflammation in unregulated conditions can induce malignant growth and tumor initiation in the surrounding tissue due to the continuous production of growth factors as well as reactive oxygen species that interact with DNA, resulting in permanent genomic alterations. In addition to the initiation of the tumor, inflammation plays a critical role in tumor progress, malignant transformation, and metastatic dissemination.46-48 Considering the inflammatory changes in various types of cancer, preventing or reversing inflammation is a decisive approach to cancer control. Numerous reports have presented evidence on the immunosuppressive properties of AM, which can help to maintain fetal-maternal tolerance during pregnancy.47,49-51 The mother’s immune system is challenged with the fetus, which must be tolerated despite the semi-allergen. However, AM is a biological barrier to supporting the homeostatic and tolerant immune milieu required for a successful pregnancy.50-51

The AM exerts immunosuppressive effects via various signaling pathways. The amniotic membrane cells (AEC and AMSC) inhibit the differentiation of monocytes into dendritic cells, thereby reducing their ability to stimulate the T lymphocytes. Both the AM cells and conditioned medium of AM inhibit peripheral blood mononuclear cell proliferation (PBMC).52 AM downregulates the expression of cell surface markers, such as CD80, CD86, and MHC II, which are
modulators of the immune response.53

Various studies have shown that cancerous cells often increase the secretion of inflammatory chemokine IL-8 in response to chemotherapeutics or other stressful environmental conditions (e.g., hypoxia).54 In this way, the IL-8 signaling also influences the proliferation,55 migration, and cancer cell invasion56 and even helps cancer cells to avoid apoptosis.50 Magatti et al. reported that AEC and AMSC inhibit the expression of IL-8 in co-culture with dendritic cells.57 It is assumed that this effect of AM can contribute to limiting the development of tumors by inhibiting inflammation.57 The AEC synthesizes the migration inhibitory factor, which is an inhibitor of the migration of macrophages.58 Furthermore, AM cells can modulate the T lymphocyte and immune lymphocytes in vitro. These cells, in particular, capable of inhibiting the allogeneic proliferation of lymphocytes.59,60 There is evidence that transplanted cryopreserved AM induces the apoptosis of macrophages, monocytes, and neutrophils; decreases the infiltration of macrophages, neutrophils, and lymphocytes; and promotes the polarization of M2 macrophages.37,38 Also, AM reduces secreted pro-inflammatory cytokines, such as TNF-α and IL-6, while it upregulates anti-inflammatory cytokines, such as IL-10, which, in turn, decreases the inflammation.61 AM cells inhibit the synthesis of inflammatory cytokines without any inflammation. This could prevent the access of growth and proangiogenic agents and enzymes that would modulate the extracellular matrix into the tumor microenvironment, thereby inhibiting/limiting further development of the tumor.62 Additionally, the conditioned medium (CM) delivered from amniotic cell culture has shown an anti-proliferative effect on lymphocytes, thus providing evidence of paracrine-mediated immunosuppressive activity.51

Interestingly, CM derived from amniotic cells plays a role in modulating the activation of human microglia (the resident immune cells in the brain and spinal cord). In vitro data showed in microglia co-cultured with hAMSCs, production of TNF-α inflammatory cytokine was suppressed.51

Clinical trials of amniotic membrane in cancer therapy and its challenges

According to the antitumor properties of amnion mentioned above, as well as its availability, cost-effectiveness, non-immunogenicity and non-tumorigenicity, this tissue and its derived cells can be considered suitable and reliable sources for cancer treatment.1,7,9,20 AM grafts may be useful as adjunctive treatment in patients with cancer. In this regard, a completed study reported on clinicaltrials.gov is Use of Human Dehydrated Amnion/chorion (DHACM) Allograft in Partial Nephrectomy.70 In this study, which the impact of DHACM allograft to facilitate the recovery of renal function in patients with kidney cancer after nephrectomy was investigated.70 There is another completed clinical trial (NCT03515954) that AM graft was secure and attached to the conjunctiva and sclera using fibrin glue in conjunctival neoplasms condition.71 However, results of two recently mentioned studies are not currently available. One clinical trial on Randomized AminoFix Study during Radical Prostatectomy is withdrawn.72 There is only one completed clinical trial with available results about AM application in cancer condition. This phase II clinical study, investigated by Sanoj Punnen at the University of Miami, and carried out on patients with prostate cancer.73 In the study, the neurovascular node that remains after prostatectomy was covered with dehydrated human AM allograft, and then the level of prostate specific antigen (PSA) in the blood was evaluated every 3 months for the first 12 months after surgery. After this, the patients were followed annually with PSA measurements and an assessment of any secondary therapies for 5 years post-surgery.73 In addition to PSA measurements, behavioral changes (the urinary leakage and erectile function) of subjects were evaluated in 140 patients, including 70 men in the control group (patients without AM allograft) and 70 men in the experimental group (patients with AM placement). The results reported on ClinicalTrials.gov.73 Certainly, future and similar research will significantly develop our knowledge of the anticancer effects of AM and thus may extend the range of clinical AM application.

However, there are some points to be considered when using amnion in the clinical setting. First, data suggest that AECs with their net anti-angiogenic and anti-proliferative effect on cancerous cells are a more appropriate source than AMSCs for the cell thera-

Amniotic membrane has angiomodulatory effect on cancerous cells

Tumor cells, due to their high growth rate, need a more extensive source of oxygen and oxygen and a more intense discharge of metabolic waste and carbon dioxide compared to normal tissues. Therefore, tumor progression is associated with neoangiogenesis and angiogenesis.53 In this context, antiangiogenic agents that prevent the emergence of new blood vessels could block the supply of nutrients and oxygen to the tumor. Studies have revealed AEC and extracellular matrix proteins of AM, e.g., collagen IV, fibronectin, and collagen VII are involved in inhibition of angiogenesis in cancer tissues.54-66

AM also secretes pigment epithelium-derived factor (PEDF), tissue inhibitor metalloprotease-1 (TIMP-1), TIMP-2, TIMP-3, and TIMP-4, thrombospondin-1 (TSP-1), IL-1 receptor antagonists (ILRIN), and IL-10, which are able to trigger the antiangiogenic process.12,20,63-65 Matrix metalloproteinases (MMPs) participate in the destruction of extracellular matrix and can therefore facilitate angiogenesis by helping cancer cells to attack the basal lamina.65 The TIMPs secreted by AM have ability to obstruct the function of MMPs.65 On the other hand, IL-10 blocks angiogenesis by inhibiting the secretion of some MMPs and promoting the secretion of TIMP-1.57 ILRIN, another protein secreted by AM, through impeding the transcriptional impact of IL-1 on cyclooxygenase-2 diminishes the expression of some potent angiogenic substances like VEGF and IL-8.68

On the contrary, it has been demonstrated that angiogenic factors, such as epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), heparin-binding EGF, hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), IL-8, IL-6, and angiopeptin-2, are secreted by AM.49,69 In a recently published article, Ling et al. demonstrated transplantation of human amniotic mesenchymal stem cells (hAMSC) in rats with premature ovarian insufficiency (POI). They reported CM derived from hAMSC (hAMSC-CM) has an effect on POI mainly through a paracrine mechanism.52 In fact, hAMSCs mediate angiogenesis through secretion of growth factors, including FGF2, insulin-like growth factor 1 (IGF-1), HGF and VEGF, thereby reducing ovarian injury, regulating follicle growth, and improving ovarian function.33 According to our previous findings, the angiogenic/antiangiogenic effect of amnion is a side-dependent manner. While the epithelial side of the amnion inhibits angiogenesis, the mesenchymal side of amnion induces angiogenesis through the release of angiogenic factors or the differentiation of its mesenchymal cells into endothelial cells.64

[Oncology Reviews 2020; 14:429]
py of angiogenesis-dependent tumors.66 Second, due to the heterogeneity of the amniotic epithelial cells, it is important to know which region of the tissue (placental AM or reflected AM) to use.74,75 Finally, providing fresh amniotic cells for therapeutic purposes is one of the clinical application challenges. Hence, it is recommended that these cells be preserved to resolve this problem and also to have a ready-to-use source for cancer cell therapy.

Although studies indicate that amniotic membrane is a promising source for cancer cell therapy, further in vitro and in vivo studies are needed to translate cancer therapy by amnion into clinical applications.

Future perspective

Nowadays, AM has wide range clinical applications, especially in tissue engineering and regenerative medicine.4-9 In this context, several companies manipulated amnion to make it more suitable for therapeutic use, and allocated a large market share. The major commercial product include amniotic fluid, amniotic membrane graft, amniotic membrane extract, amniotic membrane transplant, and amniotic cytokine extract.67 Although these products have not FDA approved, they are widely used for tissue regeneration. Considering anti-cancer properties of amnion, AM graft can be useful for treatment some type of cancers like conjunctival and skin cancer.20 AM derivatives can be also used as a vaccine for cancer prevention as previously tested in the animal model.20 Exosomeess derived from AM cells may provide a new opportunity in cancer treatment exploiting their delivery function.77 These nanovesicles may effectively transfer antitumor drugs or RNAs in the context of gene therapy to reduce the stimulatory effects of these drugs on the immune system and the hydrophilic properties that facilitate their passage through cell membranes.78-80 Translating treatment from lab to clinic requires standardization and increased the efficacy of these AM commercial products. Therefore, with sufficient standards of preservation and production of AM, and well-designed clinical trials, AM and its derivatives are suitable treatment options for cancer treatment in the future.

Conclusions

AM is now most commonly used in ophthalmology and dermatology. However, the number of studies exploring the possibilities of using AM in other clinical areas is increasing. Since the scope of AM in the case of potential treatments or prevention of cancer is a relatively new area, there are no completed clinical studies in this field. The results of preclinical studies in vitro and in vivo show that AM has selective cytotoxic effects on various types of cancer cells but does not affect normal cells. This is one of the most important advantages of the use of AM in the treatment of cancer. In addition, due to the anti-inflammatory, anti-fibrotic, pro-apoptotic, and antiangiogenic effects of AM, it could be used as a novel, safe, and inexpensive substance with fewer side effects for cancer treatment in the future and achieve desired effects. For this purpose, further studies are needed in order to elucidate the molecular mechanisms, identify the nature of factors involved in the anticancer effects of amnion, and translate cancer therapy by amnion into clinical applications.

References

1. Mamede AC, Carvalho MJ, Abrantes AM, et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res 2012;349:447-58.
2. Vidane AS, Souza AF, Sampaio RV, et al. Cat amniotic membrane multipotent cells are nontumorigenic and are safe for use in cell transplantation. Stem Cell Cloning 2014;7:71.
3. Zali H, Jafari A. Anticancer properties of amniotic membrane epithelial cells. JGPT 2016;12:22-9.
4. Dozalezi F, Nabiumi M, Jalali H. Potential use of amniotic membrane-derived scaffold for cerebrospinal fluid applications. Int J Mol Cell Med 2018;7:91.
5. Farhadhosseinabadi B, Farahani M, Tayebi T, et al. Amniotic membrane and its epithelial and mesenchymal stem cells as an appropriate source for skin tissue engineering and regenerative medicine. Artif Cells Nanomed Biotechnol 2018;46:431-40.
6. Mohan R, Bajaj A, Gundappa M. Human amnion membrane: potential applications in oral and periodontal field. J Int Soc Prev Community Dent 2017;7:15-21.
7. Peirovi H, Rezvani N, Hajinasrollah M, et al. Implantation of amniotic membrane as a vascular substitute in the external jugular vein of juvenile sheep. J Vasc Surg 2012;56:1098-104.
8. Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cells Mater 2008;15:88-99.
9. Rennie K, Gruslin A, Hengstschläger M, et al. Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells International 2012;2012:1-14.
10. Barski D, Gerullis H, Ecke T, et al. Bladder reconstruction with human amniotic membrane in a xenograft rat model: a preclinical study. Int J Med Sci 2017;14:310-18
11. Niknejad H, Yazdanpanah G. Anticancer effects of human amniotic membrane and its epithelial cells. Med Hypothes 2014;82:488-9.
12. Modaresifar K, Azizian S, Zolghadr M, et al. The effect of cryopreservation on anti-cancer activity of human amniotic membrane. Cryobiology 2017;74:61-7.
13. Khan N, Afq H, Mukhtar H. Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett 2010;293:133-43.
14. Santi A, Kugeratski FG, Zanivan S. Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics 2018;18:1700167.1-14.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
17. Zhang CL, Huang T, Wu BL, et al. Stem cells in cancer therapy: opportunities and challenges. Oncotarget 2017;8:75756-66.
18. Jenq RR, Van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nature Rev Cancer 2010;10:213-9.
19. Agraval U, Rundle P, Rennie IG, et al. Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions. Eye 2017;31:884-9.
20. Palamar M, Yaman B, Akalin T, et al. Amniotic membrane transplantation in surgical treatment of conjunctival
melanoma: long-term results. Turk J Ophthalmol 2018;48:15-8.

21. Tabatabaei M, Mosaffa N, Ghods R, et al. Vaccination with human amniotic epithelial cells confer effective protection in a murine model of colon adenocarcinoma. IJC 2018;142:1453-66.

22. Rhind N, Russell P. Signaling pathways that regulate cell division. Cold Spring Harb Perspect Biol 2012;4:1-16.

23. Sherr CJ, Bartek J. Cell cycle-targeted cancer therapies. Annu. Rev. Cancer Biol 2017;1:41-57.

24. Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair 2016;42:63-71.

25. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 2017;17:93-115.

26. Seo JH, Kim YH, Kim JS. Properties of the amniotic membrane may be applicable in cancer therapy. Med Hypotheses 2008;70:812-4.

27. Kim JC, Tseng SC. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. KJO 1995;9:32-46.

28. Kim SH, Bang SH, Kang SY, et al. Human amniotic membrane-derived stromal cells (hAMSC) interact depending on breast cancer cell type through secreted molecules. Tissue Cell 2015;47:10-6.

29. Bu S, Zhang Q, Wang Q, Lai D. Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF-β1-mediated cell cycle arrest. Int J Oncol 2017;51:1405-14.

30. Niknejad H, Khayat-Khoei M, Peirovi H. Inhibition of MMPs might increase anticancer properties of amniotic epithelial cells. Med Hypotheses 2012;5:690-1.

31. Magatti M, De Munari S, Vertua E, et al. Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. JCMM 2012;16:2208-18.

32. Wirt SE, Sage J. p107 in the public eye: an Rb understudy and more. Cell Div 2010;5:9-22.

33. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012;45:487-98.

34. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.

35. Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res Ther 2019;10:46-64.

36. Jiao H, Guan F, Yang B, et al. Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the Bel-2/caspase pathways. Mol Biol Rep 2012;39:467-73.

37. Tseng SC. HC-HA/PTX3 purified from amniotic membrane as novel regenerative matrix: insight into relationship between inflammation and regeneration. Invest Ophthalmol Vis Sci 2016;57:ORSFh1-8.

38. Bauer D, Hennig M, Wasmuth S, et al. Amniotic membrane induces peroxisome proliferator-activated receptor-γ positive alternatively activated macrophages. Invest Ophthalmol Vis Sci 2012;53:799-810.

39. Mamede AC, Guerra S, Laranjo M, et al. Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma. Med Oncol 2015;32:257.

40. Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. Cytotherapy 2014;16:33-40.

41. Rodina A, Vilenchik M, Moulick K, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2003;498-507.

42. Niknejad H, Yazdanpanah G, Mirmasoumi M, et al. Inhibition of HSP90 could be possible mechanism for anti-cancer property of amniotic membrane. Med Hypotheses 2013;81:862-5.

43. Li H, Niederkorn JY, Neelam S, et al. Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci 2005;46:900-7.

44. Rossin A, Miloro G, Hueber AO. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers 2019;11:639.

45. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.

46. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature Rev Cancer 2011;11:85-95.

47. Mamede AC, Laranjo M, Carvalho MJ, et al. Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study. J Membr Biol 2014;247:357-60.

48. Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.

49. Ramuta TŽ, Kreft ME. Human amniotic membrane and amniotic membrane–derived cells: how far are we from their use in regenerative and reconstructive urology? Cell Transplant 2018;27:77-92.

50. Kang NH, Hwang KA, Kim SU, et al. Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells. Cancer Gene Ther 2012;19:517-22.

51. Magatti M, Vertua E, Cargnoni A, et al. The immunomodulatory properties of amniotic epithelial cells: two sides of the coin. Cell Transplant 2018;27:31-44.

52. Magatti M, De Munari S, Vertua E, et al. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant 2009;18:899-914.

53. He H, Li W, Chen SY, et al. Amniotic membrane extract suppresses activation and induces apoptosis in RAW264. 7 cells. Invest Ophthalmol Vis Sci 2008;49:4468-75.

54. Vaugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.

55. Takamori H, Oades ZG, Hoch RC, et al. Autocrine growth effect of IL-8 and GROα on a human pancreatic cancer cell line, capan-1. Pancreas 2000;21:52-6.

56. Yao C, Lin Y, Chua MS, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor–negative breast cancer cells. Int J Cancer 2007;121:1949-57.

57. Magatti M, Caruso M, De Munari S, et al. Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocyte-derived dendritic cell differentiation.
tation and function. Cell Transplant 2015;24:1733-52.
58. Chang CJ, Yen ML, Chen YC, et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-γ. Stem Cells 2006;24:2466-77.
59. Laranjeira P, Duque M, Vojtek M, et al. Amniotic membrane extract differentially regulates human peripheral blood T cell subsets, monocyte subpopulations and myeloid dendritic cells. Cell Tissue Rev 2018;1:1-18.
60. Pianta S, Signoroni PB, Muradore I, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Threg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev 2015;11:394-407.
61. He H, Li W, Chen SY, et al. Suppression of activation and induction of apoptosis in RAW264.7 cells by amniotic membrane extract. Invest Ophthalmol Vis Sci 2008;49:4468-75.
62. Han Y, Jo H, Cho JH, et al. Resveratrol as a tumor-suppressive nutraceutical modulating tumor microenvironment and malignant behaviors of cancer. Int J Mol Sci 2019;20:925.
63. Katayama Y, Uchino J, Chihara Y, et al. Tumor neoangiogenesis and developments in therapeutics. Cancers 2019;11:316.
64. Niknejad H, Paeini-Vayghan G, Tehrani FA, et al. Side dependent effects of the human amnion on angiogenesis. Placenta 2013;34:340-5.
65. Roubelakis MG, Tsaknakis G, Pappa KI, et al. Spindle shaped human mesenchymal stem/stromal cells from amniotic fluid promote neoangiogenesis. PLoS One 2013;8:e54747.
66. Niknejad H, Yazdanpanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. Cell Tissue Res 2016;363:599-608.
67. Hossain L, Siddika A, Adnan MH, et al. Human amniotic membrane and its anti-cancer mechanism: a good hope for cancer therapy. SN Comp Clin Med 2019;1:1-9.
68. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
69. Koob TJ, Lim JJ, Massie M, et al. Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. Vasc Cell 2014;6:10.
70. MiMedx Group, Inc. Use of human dehydrated amnion/chorion (DHACM) allograft in partial nephrectomy. NLM identifier: NCT03323021. Accessed: Aug 12, 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03323021?term=amniotic+membrane&cond=Cancer&rank=5
71. Benha University. AS-OCT guided treatment of diffuse CSCC. NLM identifier: NCT03515954. Accessed: Aug 12, 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03515954?term=amniotic+membrane&cond=Cancer&rank=2
72. M.D. Anderson Cancer Center. Randomized AminoFix Study during Radical Prostatectomy. NLM identifier: NCT02645591. Accessed: Aug 12, 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02645591?term=amniotic+membrane&cond=Cancer&rank=3
73. Punnen S. Miami membrane for potency (MMEP) trial (MMEP). NLM identifier: NCT02710422. Accessed: Aug 12, 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02710422?term=amniotic+membrane&cond=Cancer&rank=1
74. Banerjee A, Weidinger A, Hofer M, et al. Different metabolic activity in placental and reflected regions of the human amniotic membrane. Placenta 2015;36:1329-32.
75. Nourazarian S.M, Nourazarian A, Roshani Asl E. Investigate the Inhibitory effect of Amniotic membrane proteins on HSP90 gene Expression level in PC3 Prostate cell line. Bull Env Pharmacol Life Sci 2015;4:61-5.
76. Murri MS, Moshirfar M, Birdsong OC, et al. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol (Auckland, NZ) 2018;12:1105-12.
77. Zhang Q, Sun J, Huang Y, et al. Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring microRNAs against apoptosis. Mol Ther-Nucl Acids 2019;16:407-18.
78. Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomed Nanotechnol Biol Med 2016;12:655-64.
79. Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceuticals 2018;10:218-58.
80. Bunggulawa EJ, Wang W, Yin T, et al. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnol 2018;16:81-94.